Clinical trial
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung…
NCT00049543 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00049543 |
|---|---|
| Title | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery |
| Official title | A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | gefitinib, placebo, laboratory biomarker analysis |
| Enrollment | 503 |
| Start date | Sep 1, 2002 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 1, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: